Professional antigen-presenting cells (APC), e.g. dendritic cells, express immuno-proteasome components and process proteins for MHC presentation differently from non-immune cells. Thus, they induce reactivities against sets of peptides that do not overlap with those generated by non-professional AP
In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells
✍ Scribed by Matteo Bellone; Giandomenica Iezzi; Angelo A. Manfredi; Maria Pia Protti; Paolo Dellabona; Giulia Casorati; Claudio Rugarli
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 934 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Cytotoxic T lymphocytes (CTL) recognize antigenic peptides presented by major histocompatibility complex class I (MHC‐I) molecules on the surface of target cells. Optimal induction of CD8^+^ CTL depends on the amount of relevant peptide/MHC‐I complexes and the presence of co‐stimulatory molecules on antigen‐presenting cells (APC). The antigen‐processing defective mutant cell line RMA‐S, when cultured at low temperature, expresses high amounts of MHC‐I molecules that do not contain endogenously derived peptides. These “empty” MHC‐I molecules can be stabilized by addition of MHC‐binding peptides. RMA‐S cultured at low temperatures with selected peptides have been used for in vitro CTL induction with conflicting results. RMA‐S cells do not express detectable amounts of B7 co‐stimulatory molecule. This could explain their unpredictable efficiency as APC. We have evaluated whether RMA‐S cells, stably transfected with cDNA encoding for the human B7.1 molecule could provide effective co‐stimulation for CD8^+^ T lymphocytes. RMA‐S/B7 cells, loaded with different synthetic peptides, demonstrated a high and sometimes unique efficiency for in vitro primary CTL induction, even when “sub‐optimal” antigen peptides were used. Most importantly, RMA‐S/B7 cells pulsed with naturally processed peptides extracted from the poorly immunogenic B16 melanoma cells were able to prime CD8^+^ cells against B16 melanoma. We conclude that the use of RMA‐S/B7 cells as APC represents an ideal strategy for in vitro CTL immunization without prior in vivo priming. This system may also help to address the issue of the different contributions of co‐stimulation and relative occupancy of MHC‐I by single peptide epitopes in CTL priming.
📜 SIMILAR VOLUMES
## Abstract The requirements for the conversion of CD8^+^ memory T cells into effector class I major histocompatibility complex (MHC) K^d^−restricted cytotoxic T (T~c~) cells __in vitro__ have been studied. Purified CD8^+^splenocytes from influenza A/WSN‐primed BALB/c (H‐2^d^) mice stimulated with
## BACKGROUND. Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8 + T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors. METHODS. We used a population o